Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors
- Conditions
- Eye CancerMetastatic Breast CancerLung Cancer
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT06643884
- Locations
- 🇺🇸
Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Massachusetts Eye and Ear, Boston, Massachusetts, United States
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
- Conditions
- Ocular MelanomaUveal MelanomaChoroidal MelanomaIndeterminate Lesions
- Interventions
- Device: Sham Infrared LaserDevice: Suprachoroidal MicroinjectorDevice: Sham MicroinjectorDevice: Infrared Laser
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 100
- Registration Number
- NCT06007690
- Locations
- 🇨🇿
Fakultni Thomayerova nemocnice, Praha 4, Krč, Czechia
🇺🇸Retina Consultants of Alabama, Birmingham, Alabama, United States
🇩🇪Charité - Universitätsmedizin Berlin KöR, Berlin, Germany
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
- Conditions
- Non-muscle-invasive Bladder CancerMuscle-Invasive Bladder Carcinoma
- Interventions
- Combination Product: AU-011 in Combination with Medical Laser AdminstrationCombination Product: AU-011 in Combination with Medical Laser Administration
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 21
- Registration Number
- NCT05483868
- Locations
- 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States
🇺🇸Urology Associates, P.C., Nashville, Tennessee, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
- Conditions
- Choroidal MelanomaIndeterminate Lesions
- Interventions
- Other: Standard of Care
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 2
- Registration Number
- NCT05266430
- Locations
- 🇺🇸
University of Wisconsin Dept of Ophthalmology & Visual Sciences, Madison, Wisconsin, United States
🇺🇸Retina Consultants of Texas, Bellaire, Texas, United States
🇺🇸Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
- Conditions
- Uveal MelanomaOcular MelanomaChoroidal Melanoma
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 22
- Registration Number
- NCT04417530
- Locations
- 🇺🇸
UCLA Jules Stein Eye Institute, Los Angeles, California, United States
🇺🇸St. Thomas Health / Tennessee Retina, PC, Nashville, Tennessee, United States
🇺🇸Midwest Eye Institute, Carmel, Indiana, United States
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
- Conditions
- Choroidal MelanomaIndeterminate Lesions of Eye
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 500
- Registration Number
- NCT03941379
- Locations
- 🇺🇸
Retina Associates SW, P.C., Tucson, Arizona, United States
🇺🇸St. Thomas Health / Tennessee Retina, PC, Nashville, Tennessee, United States
🇺🇸Byers Eye Institute at Stanford University, Palo Alto, California, United States
Study in Subjects With Small Primary Choroidal Melanoma
- Conditions
- Ocular MelanomaUveal MelanomaChoroidal Melanoma
- Interventions
- Device: Laser Activation
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Aura Biosciences
- Target Recruit Count
- 57
- Registration Number
- NCT03052127
- Locations
- 🇺🇸
UCLA Jules Stein Eye Institute, Los Angeles, California, United States
🇺🇸Associated Retinal Consultants, PC, Royal Oak, Michigan, United States
🇺🇸Retina Consultants of Houston, Houston, Texas, United States